Oral hypoglycaemic agents for diabetes in pregnancy - An appraisal of the current evidence for oral anti-diabetic drug use in pregnancy

Annals of the Academy of Medicine Singapore

Volumn 36, Issue 8, 2007, Pages 672-678

  Ho, Francis L W ^a   Liew, Choon Fong ^a   Cunanan, Elaine C ^a   Lee, Kok Onn ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Acarbose; Gestational diabetes; Glyburide; Metformin

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLIPIZIDE; INSULIN; METFORMIN; ROSIGLITAZONE; SULFONYLUREA; TESTOSTERONE;

DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INSULIN RESISTANCE; OVARY POLYCYSTIC DISEASE; PREECLAMPSIA; PREGNANCY; PREGNANCY DIABETES MELLITUS; REVIEW;

EID: 34548498431     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Yogev Y, Langer O. The use of anti-hyperglycaemic and hypoglycaemic agents in pregnancy. Fetal Matern Med Rev 2004;15:133-43.
2. Smithberg M, Runner MN. Teratogenic effects of hypoglycemic treatments in inbred strains of mice. Am J Anat 1963;113:479-89.
3. Smoak IW. Embryopathic effects of the oral hypoglycemic agent chlorpropamide in cultured mouse embryos. Am J Obstet Gynecol 1993;169:409-14.
4. Denno KM, Sadler TW. Effects of the biguanide class of oral hypoglycemic agents on mouse embryogenesis. Teratology 1994;49:260-66.
5. Campbell GD. Chlorpropamide and foetal damage. BMJ 1963;1:59-60.
6. Larsson Y, Sterky G. Possible teratogenic effect of tolbutamide in a pregnant prediabetic. Lancet 1960;2:1424-6.
7. Notelovitz M. Sulphonylurea therapy in the treatment of the pregnant diabetic. S Afr Med J 1971;45:226-9.
8. Zucker P, Simon G. Prolonged symptomatic neonatal hypoglycemia associated with maternal chlorpropamide therapy. Pediatrics 1968;42:824-5.
9. Kemball ML, McIver C, Milner RD, Nourse CH, Schiff D, Tiernan JR. Neonatal hypoglycaemia in infants of diabetic mothers given sulphonylurea drugs in pregnancy. Arch Dis Child 1970;45:696-701.
10. Hellmuth E, Damm P, Molsted-Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med 2000;17:507-11.
11. Elliot BD, Langer O, Schenker S, Johnson RF. Insignificant transfer of glyburide occurs across the human placenta. Am J Obstet Gynecol 1991;165:807-12.
12. Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000;343:1134-8.
13. Kremer CJ, Duff P. Glyburide for the treatment of gestational diabetes. Am J Obstet Gynecol 2004;190:1438-9.
14. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:524-9.
15. Glueck CJ, Goldenberg N, Wang P, Loftspring M, Sherman A. Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum Reprod 2004;19:510-21.
16. Glueck CJ, Wang P, Kobayashi S, Phillips H, Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002;77:520-5.
17. Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod 2004;19:1323-30.
18. Glueck CJ, Bornovali S, Pranikoff J, Goldenberg N, Dharashivkar S, Wang P. Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. Diabet Med 2004;21:829-36.
19. Coetzee EJ, Jackson WP. Metformin in management of pregnant insulin-independent diabetics. Diabetologia 1979;16:241-5.
20. Coetzee EJ, Jackson WP. Pregnancy in established non-insulin-dependent diabetics. A five-and-a-half year study at Groote Schuur Hospital. S Afr Med J 1980;58:795-802.
21. Zarate A, Ochoa R, Hernandez M, Basurto L. Effectiveness of acarbose in the control of glucose tolerance worsening in pregnancy. Ginecol Obstet Mex 2000;68:42-5.
22. Yaris F, Yaris E, Kadioglu M, Ulku C, Kesim M, Kalyoncu NI. Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. Reprod Toxicol 2004;18:619-21.
23. Kalyoncu NI, Yaris F, Ulku C, Kadioglu M, Kesim M, Unsal M, et al. A case of rosiglitazone exposure in the second trimester of pregnancy. Reprod Toxicol 2005;19:563-4.
24. Chan LY, Yeung JH, Lau TK. Placental transfer of rosiglitazone in the first trimester of human pregnancy. Fertil Steril 2005;83:955-8.
25. Simmons D, Walters BN, Rowan JA, McIntyre HD. Metformin therapy and diabetes in pregnancy. Med J Aust 2004;180:462-4.
26. Drug Facts and Comparisons 2003. St. Louis, Mo: Facts & Comparisons Ltd, 2003.
27. Physicians Desk Reference 2003. Montvale, NJ: Thompson, 2003.
28. Langer O. Gestational diabetes and oral hypoglycemic agents. OBG Management 2003;15:62-76.
29. Langer O. When diet fails: insulin and oral hypoglycemic agents as alternatives for the management of gestational diabetes mellitus. J Matern Fetal Neonatal Med 2002;11:218-25.
30. Langer O. Insulin and other treatment alternatives in gestational diabetes mellitus. Prenatal Neonatal Med 1998;3:542-9.
31. Langer O. Oral hypoglycemic agents in pregnancy: their time has come. J Matern Fetal Neonatal Med 2002;12:376-83.